GETI-BNasdaq StockholmHealth CareIFRS · SEK

Getinge

Getinge AB is a global provider of products and solutions for healthcare and life sciences, focusing on intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life sciences. The company employs approximately 12,000 people worldwide and operates in over 135 countries. In 2024, Getinge reported strong growth in sales and order intake, particularly in ventilators and consumables for ECLS and Sterile Transfer. The company is headquartered in Gothenburg, Sweden, and continues to expand its product portfolio through strategic acquisitions like Paragonix Technologies, Inc.

Ask about the company
Revenue35.0bn SEK
+0.6 %y/y
Operating profit (EBIT)3,789m SEK
+32.8 %y/y
EBIT margin10.8%
+2.6 ppy/y
Net income2,276m SEK
+37.6 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

010203040bn SEK2020: 29.8 bn SEK2020: EBIT 4.8 bn SEK20202021: 27.0 bn SEK2021: EBIT 4.4 bn SEK20212022: 28.3 bn SEK2022: EBIT 3.6 bn SEK20222023: 31.8 bn SEK2023: EBIT 3.7 bn SEK20232024: 34.8 bn SEK2024: EBIT 2.9 bn SEK20242025: 35.0 bn SEK2025: EBIT 3.8 bn SEK202535.03.8
RevenueOperating profit (EBIT)
Ask Clarifo about Getinge

Business

Share of revenue
Intensive Care30 %

Includes ventilators and related equipment for critical care environments.

Cardiovascular Procedures20 %

Products for cardiovascular surgeries and interventions.

Operating Rooms15 %

Equipment and solutions for surgical environments.

Sterile Reprocessing15 %

Solutions for sterilization and infection control.

Life Sciences10 %

Products for research and development in life sciences.

ECLS and Transplant Care10 %

Consumables and systems for extracorporeal life support and organ transplant.

Customers

Getinge serves a diverse range of customers in the healthcare and life sciences sectors, including hospitals, surgical centers, and research institutions. The company's products are critical for intensive care units, operating rooms, and laboratories, making them essential for healthcare providers globally. Customers value Getinge's solutions for their reliability, innovation, and ability to enhance patient outcomes. The company's recent focus on expanding its transplant care offerings has attracted attention from specialized medical centers.

Hospitals

Purchase intensive care and cardiovascular products for critical care.

Surgical Centers

Acquire operating room equipment for surgical precision.

Research Institutions

Utilize life science products for scientific studies.

Specialized Medical Centers

Interested in ECLS and transplant care systems.

Strategy

Getinge's strategic priorities include enhancing productivity and cost efficiency through structural measures, focusing on high-growth areas like ECLS and transplant care, and phasing out less profitable segments such as surgical perfusion. The company aims to leverage its strong cash flow and earnings to drive profitability and sustain long-term growth. Strategic acquisitions, like that of Paragonix Technologies, are central to expanding its product portfolio and market presence.

Enhancing productivity and cost efficiencyMedium term

To strengthen operating margins and profitability.

Focusing on high-growth areasLong term

To capture market opportunities in ECLS and transplant care.

Phasing out surgical perfusionShort term

To reallocate resources to more profitable segments.

Geography

Getinge operates globally, with a strong presence in Europe, North America, and Asia. The company is headquartered in Gothenburg, Sweden, and its products are sold in more than 135 countries. This extensive geographic reach allows Getinge to tap into diverse markets and mitigate regional risks. The company's strategic acquisitions, such as Paragonix Technologies, enhance its product offerings and market penetration in key regions.

Risks

Getinge faces several risks, including geopolitical uncertainties and potential trade barriers that could impact its global operations. The company's decision to phase out the surgical perfusion segment reflects the risk of limited market growth and unsatisfactory market share. Additionally, the healthcare industry is subject to regulatory changes that could affect product approvals and market access. Currency fluctuations and economic downturns in key markets also pose financial risks.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Geopolitical uncertainties1Regulatory changes2Currency fluctuations3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Geopolitical uncertaintiesImpact: HighLikelihood: Medium

    Potential trade barriers could impact global operations.

  2. Regulatory changesImpact: HighLikelihood: Medium

    Could affect product approvals and market access.

  3. Currency fluctuationsImpact: MediumLikelihood: Low

    Impact financial performance due to global operations.

  4. Limited market growth in surgical perfusionImpact: Medium

    Market share is unsatisfactory, leading to strategic phase-out.

Ask Clarifo about Getinge

Accounting

Judgemental items
Revenue recognition timing

Affects sales and delivery reporting.

Impact: Significant

Seasonal demand fluctuations

Impact quarterly revenue comparability.

Impact: Moderate

Valuation of acquired intangibles

Requires significant judgment post-acquisitions.

Impact: Significant

Currency translation adjustments

Affect financial results due to international operations.

Impact: Moderate

Similar listed companies

Publicly listed companies with a comparable business focus.

Trelleborg

TREL-B · Industrials

Essity A

ESSITY-B · Consumer Staples

AddLife

ALIF-B · Health Care

Medline Inc.

MDLN · Surgical & Medical Instruments & Apparatus

Vitrolife

VITR · Health Care

STERIS plc

STE · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Last updated: 24/09/2026